Metraipolis › archive › dc_a28dbebb9afc

Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study — Europe PMC PMID:42180598

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42180598
DOI
10.1016/j.ahjo.2026.100795
License (as archived)
solo-consultazione
Archived
2026-11-02T13:49:37.716Z
SHA-256 of the archived text
5c2c2d44ac884cb4854bf9e1befe453c619156cd9edd1aabe800e4ba21fb2855
Stable URL of this page
https://metraipolis.com/documento/dc_a28dbebb9afc

How to cite

Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study — Europe PMC PMID:42180598 — Europe PMC (en), https://europepmc.org/article/MED/42180598 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a28dbebb9afc (Metraipolis archive dc_a28dbebb9afc, sha256 5c2c2d44ac884cb4854bf9e1befe453c619156cd9edd1aabe800e4ba21fb2855)
BibTeX
@misc{dca28dbebb9afc,
  title = {Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study — Europe PMC PMID:42180598},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42180598},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a28dbebb9afc; sha256 5c2c2d44ac884cb4854bf9e1befe453c619156cd9edd1aabe800e4ba21fb2855},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180598. Agents can read the archived copy with the MCP tool read_document.